EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Bruton's Tyrosine Kinase: Pathophysiological Roles and Inhibitor‐Based Therapeutic Advances

Simhadri Goud Gundrathi, Bharat Kumar Reddy Sanapalli iD, Shrestha Palit, Dilep Kumar Sigalapalli, Ashwini Deshpande, Vidyasrilekha Sanapalli

Cell Biochemistry and Function · 2026

DOI: 10.1002/cbf.70174 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cell Biochemistry and Function, 2026. Verfasst von Simhadri Goud Gundrathi und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy & Technology Management, SVKM's Narsee Monjee Institute of Management Studies (NMIMS) Deemed-to-be-University, Hyderabad Campus, J…. Hauptthemen laut MEDLINE: Agammaglobulinaemia Tyrosine Kinase, Protein Kinase Inhibitors. Die Arbeit nennt 47 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bruton's tyrosine kinase (BTK) plays a pivotal role in intracellular signaling within B‐cells, governing development, differentiation, and survival, and is an integral target in treating B‐cell malignancies and autoimmune disorders. The impact on B‐cell receptor, Toll‐like receptor, and chemokine receptor pathways establishes its therapeutic interest. This review integrates existing studies on BTK functional roles in immunology and BTK inhibitors (BTKis) targeting. Literature was ascertained by searching prominent databases such as PubMed, Embase, Web of Science and Google scholar for BTK's molecular biology, the history of BTKis and their clinical significance. The review addresses mechanisms of resistance, particularly the C481S mutation, which impedes covalent inhibition but is abrogated by non‐covalent BTKis like pirtobrutinib, including BTK's application in autoimmune and inflammatory disorders, and discusses the importance of further long‐term safety and efficacy in chronic diseases. BTK inhibitors have proven to be an essential part of targeted therapy for B‐cell cancer, and continuing advances are addressing challenges like drug resistance and side effects. However, major challenges like the emergence of novel resistance mutations, the need for accurate biomarkers to direct therapy, and the continuing challenge of controlling drug‐associated toxicities and maintaining costs under control still pertain. Ongoing research is essential to fully realize the therapeutic potential of BTK inhibitors and integrate them into personalized regimens for cancer and immune diseases alike.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Agammaglobulinaemia Tyrosine KinaseProtein Kinase InhibitorsHumansAutoimmune DiseasesAnimalsB-Lymphocytes

Stichwörter der Autor:innen

BTK inhibitorsBruton's tyrosine kinaseB‐cell receptor signalingautoimmune diseasestargeted therapy

Substanzen

Agammaglobulinaemia Tyrosine KinaseProtein Kinase InhibitorsBTK protein, human

Autor:innen und Institutionen

  • School of Pharmacy & Technology Management, SVKM's Narsee Monjee Institute of Management Studies (NMIMS) Deemed-to-be-University, Hyderabad Campus, Jadcherla, Telangana, India.
  • Department of Pharmacology, School of Pharmacy & Technology Management, SVKM's Narsee Monjee Institute of Management Studies (NMIMS) Deemed-to-be-University, Hyderabad Campus, Jadcherla, Telangana, India.
  • Department of Biochemistry, University of Washington, Seattle, USA.
  • Department of Pharmaceutics, School of Pharmacy & Technology Management, SVKM's Narsee Monjee Institute of Management Studies (NMIMS) Deemed-to-be-University, Hyderabad Campus, Jadcherla, Telangana, India.
  • Department of Pharmaceutical Chemistry, School of Pharmacy & Technology Management, SVKM's Narsee Monjee Institute of Management Studies (NMIMS) Deemed-to-be-University, Hyderabad Campus, Jadcherla, Telangana, India.

ORCID-Profile: Bharat Kumar Reddy Sanapalli

Zitieren

APA

Gundrathi, S. G., Sanapalli, B. K. R., Palit, S., Sigalapalli, D. K., Deshpande, A., & Sanapalli, V. (2026). Bruton's Tyrosine Kinase: Pathophysiological Roles and Inhibitor‐Based Therapeutic Advances. Cell Biochemistry and Function. https://doi.org/10.1002/cbf.70174

Vancouver

Gundrathi SG, Sanapalli BKR, Palit S, Sigalapalli DK, Deshpande A, Sanapalli V. Bruton's Tyrosine Kinase: Pathophysiological Roles and Inhibitor‐Based Therapeutic Advances. Cell Biochemistry and Function. 2026. doi:10.1002/cbf.70174

BibTeX
@article{Gundrathi2026,
  author = {Gundrathi, Simhadri Goud and Sanapalli, Bharat Kumar Reddy and Palit, Shrestha and Sigalapalli, Dilep Kumar and Deshpande, Ashwini and Sanapalli, Vidyasrilekha},
  title = {Bruton's Tyrosine Kinase: Pathophysiological Roles and Inhibitor‐Based Therapeutic Advances},
  journal = {Cell Biochemistry and Function},
  year = {2026},
  doi = {10.1002/cbf.70174}
}
Kostenlos starten →